Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cinclus Pharma Holding AB ( (SE:CINPHA) ) just unveiled an update.
Cinclus Pharma Holding AB is hosting a virtual event featuring Professor Prateek Sharma to discuss the treatment landscape and unmet medical needs for erosive GERD patients, highlighting their drug candidate linaprazan glurate. This event underscores Cinclus Pharma’s commitment to advancing GERD treatment and could enhance their positioning in the pharmaceutical industry by addressing significant patient needs.
The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.
More about Cinclus Pharma Holding AB
Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Their leading drug candidate, linaprazan glurate, aims to treat gastroesophageal reflux disease (GERD) more effectively than current treatments, with ongoing Phase III studies.
Average Trading Volume: 64,496
Technical Sentiment Signal: Hold
Current Market Cap: SEK791.1M
For an in-depth examination of CINPHA stock, go to TipRanks’ Overview page.